Disease · HP_0002239

Gastrointestinal hemorrhage

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Gastrointestinal hemorrhage. Diseases, record HP_0002239. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002239

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Gastrointestinal hemorrhage; Open Targets
Open Targets ID: HP_0002239; Open Targets
Other names: GI haemorrhage, GI hemorrhage, Gastrointestinal bleeding, Gastrointestinal haemorrhage; Open Targets
NCI Thesaurus: C48592; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 7 of its 22 drugs, from ClinicalTrials.gov; Open Targets

Drugs22

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TRANEXAMIC ACID	CHEMBL877	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ERYTHROMYCIN	CHEMBL532	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FERRIC CARBOXYMALTOSE	CHEMBL2108597		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FERRIC OXYHYDROXIDE	CHEMBL4802224	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
FERROUS SULFATE	CHEMBL1200830	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
IRON ISOMALTOSIDE 1000	CHEMBL4298046		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
PENTOSAN POLYSULFATE SODIUM	CHEMBL1201516	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
THALIDOMIDE	CHEMBL468	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
OCTREOTIDE	CHEMBL1680	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 22

See all 22 drugs

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CRBN	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2	https://conductscience.org/library/genes/1642	Drugs and targets
F10	Coagulation factor X	2	Coagulation factor X inhibitor	Unknown	https://conductscience.org/library/genes/2159	Drugs and targets
RBX1	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2	https://conductscience.org/library/genes/9978	Drugs and targets
SSTR1	Somatostatin receptor	2	Somatostatin receptor 1 agonist; Somatostatin receptor agonist	Phase 2	https://conductscience.org/library/genes/6751	Drugs and targets
SSTR2	Somatostatin receptor	2	Somatostatin receptor 2 agonist; Somatostatin receptor agonist	Phase 2	https://conductscience.org/library/genes/6752	Drugs and targets
SSTR3	Somatostatin receptor	2	Somatostatin receptor 3 agonist; Somatostatin receptor agonist	Phase 2	https://conductscience.org/library/genes/6753	Drugs and targets
SSTR5	Somatostatin receptor	2	Somatostatin receptor 5 agonist; Somatostatin receptor agonist	Phase 2	https://conductscience.org/library/genes/6755	Drugs and targets
ADRA1A	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/148	Drugs and targets

1 to 10 of 30

See all 30 targets

Trials23

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02460458	Type 3 Von Willebrand International Registries Inhibitor Prospective Study		265	2016-04-19	Type 3 Von Willebrand's Disease	VON WILLEBRAND FACTOR HUMAN	Its record names the disease	ClinicalTrials.gov
NCT00964496	Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation	Phase 2	55	2010-04-30	Obscure Gastrointestinal Bleeding, Angiodysplasia, Gastric Antral Vascular Ectasia, Thalidomide	THALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT01707225	Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)	Phase 1	10	2016-01-12	Gastrointestinal Bleeding	OCTREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT01947959	Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)		665,533		Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome	RIVAROXABAN	Its record names the disease	ClinicalTrials.gov
NCT02468102	Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)		99,999		Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation	RIVAROXABAN	Its record names the disease	ClinicalTrials.gov
NCT04818151	Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data		14,914		Venous Thromboembolic Disease, Kidney Failure, Chronic	APIXABAN, WARFARIN	Its record names the disease	ClinicalTrials.gov
NCT01658124	Haemorrhage Alleviation With Tranexamic Acid- Intestinal System	Phase 3	12,009		Gastrointestinal Bleeding	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT07533721	Ibuprofen vs Expectant Management for hsPDA in Preterm Infants: Retrospective Cohort		541		Patent Ductus Arteriosus, Infant, Premature	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT03840057	Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy	Phase 2	435		Gastro Intestinal Bleeding, Upper Gastrointestinal Bleeding	AZITHROMYCIN, METOCLOPRAMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00259220	HDUPE 2004: Gastro-Oesophageal Haemorrhage in Emergency : Gastric Préparation to Endoscopy	Phase 3	270		Upper Gastrointestinal Bleeding	ERYTHROMYCIN	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 23

See all 23 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Thalidomide Group vs Iron-controlled Group: Cessation of Bleeding	13 of 28	0 of 27	55	NCT00964496	Trial comparisons
Thalidomide Group vs Iron-controlled Group: Participants Dependent on Blood Transfusions	3 of 28	13 of 27	55	NCT00964496	Trial comparisons
Thalidomide Group vs Iron-controlled Group: Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months	20 of 28	1 of 27	55	NCT00964496	Trial comparisons
Thalidomide Group vs Iron-controlled Group: serious adverse events	0 of 28	0 of 27	55	NCT00964496	Trial comparisons

Papers from its trials18

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37356632	RESULT	1	PubMed
37206079	RESULT	1	PubMed
36741070	RESULT	1	PubMed
32088712	RESULT	1	PubMed
29564926	RESULT	1	PubMed
25569028	RESULT	1	PubMed
19832693	RESULT	1	PubMed
16601430	RESULT	1	PubMed
11961015	RESULT	1	PubMed
41860133	DERIVED	1	PubMed

1 to 10 of 18

See all 18 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0002239

GET https://conductscience.org/api/diseases/v1/HP_0002239/drugs?page=2

API reference For AI assistants